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Abstract 
 
Background and aims: Using smoking cessation medications for several weeks prior to 
quitting smoking facilitates quitting success, but how it does so is not clear. Candidate 
theories are that pre-cessation medication enhances self-efficacy, facilitates medication 
adherence post-quit, induces aversion to smoking, reduces reward from smoking, or reduces 
the drive to smoke. We investigated these pathways using data from a large trial of nicotine 
preloading, using mediation analysis.  
 
Design: Randomised controlled trial of nicotine preloading. Potential mediators were 
assessed at baseline and one week into the pre-loading (three weeks prior to quitting). In 
addition to this, urges to smoke in abstainers were assessed one week after the target quit 
date. 
 
Setting: England. 
 
Participants: 1792 smokers who wanted to quit attending specialist smoking cessation 
services in England were enrolled between 13/08/2012 and 10/03/2015. 
Intervention and comparator: Participants were randomised to either standard smoking 
cessation medications accompanied by behavioural support or the same treatment 
supplemented by nicotine ‘preloading’, i.e. four weeks of 21mg nicotine patch use prior to 
quitting. 
 
Measurements: The primary outcome, selected for its proximity in time to potential 
mediators, was biochemically validated abstinence from smoking at four weeks post target 
quit date. Potential mediators included Modified Cigarette Evaluation Questionnaire with 
subscales assessing satisfaction, reward, craving and aversion; ratings of strength and 
frequency of urges to smoke; Mood and Physical Symptoms Scale assessing cigarette 
withdrawal symptoms; two items from Nicotine Dependence Syndrome Scale assessing 
smoking stereotypy; self-reported reduction in cigarettes per day and in CO reading; post-
TQD medication adherence; self-efficacy; nausea. 
 
Findings: Preloading reduced urges to smoke at three weeks pre-quit (p<0.001) and exhaled 
CO concentrations (p<0.001), and also urges to smoke post-quit in abstainers (p=0.001). At 
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three weeks pre-quit, it also reduced cigarette consumption, enjoyment of and satisfaction 
from smoking and smoking reward and increased nausea, aversion (all p<0.001) and smoking 
stereotypy (p=0.003). Only the first three variables however (reduced smoke intake and 
reduced urges to smoke pre- and post-quit) mediated abstinence from smoking at 4 weeks 
and only the latter two mediated abstinence at six months (indirect mediating effects 
p<0.05).   
 
Conclusions: Nicotine preloading appears to facilitate smoking abstinence by reducing urges 
to smoke and smoke intake before quitting and urges to smoke after quitting. 
 
Registration 
Current Controlled Trials, ISRCTN33031001. 
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Background 
The medications that are currently licensed for smoking cessation (nicotine replacement 
therapy (NRT), bupropion, and varenicline) are likely to work along somewhat different 
physiological pathways, but they have similar effects on smokers in that they all reduce the 
intensity and frequency of urges to smoke. This effect can have two discrete manifestations, 
with different treatment implications.  
 
1.  The medications alleviate withdrawal discomfort after a smoker has stopped smoking (1–
3).  This was the effect that originally allowed the medicinal licensing of NRT because 
medicinal regulations required that a drug affects a disease or a symptom; ‘craving reduction’ 
satisfied the latter requirement (‘nicotine dependence’ became officially a disease only after 
the publication of DSM-III in 1980). Partly because of this focus on post-cessation urges to 
smoke, and partly because of concerns about nicotine overdose if NRT was used while 
smokers still smoked, , NRT was only provided after smokers quit smoking in the initial 
licensing. Later licensing of the other two medications, bupropion and varenicline, followed a 
similar pattern. Although bupropion and varenicline are used for 7-14 days prior to quitting, 
this is to allow patients to habituate to medication effects and dose increases rather than 
aimed at increasing treatment effects.  
 
2. In contrast to the post-quit effects both NRT and varenicline and probably also bupropion 
exert their ‘craving reduction’ effects also while smokers still smoke (4–7). This might also 
assist with smoking cessation. Attempts have been made to harness this effect by instigating 
medication use over a period of time prior to the Target Quit Day (TQD) while smokers 
smoke ad-lib (an intervention that has become known as preloading). In theory, this approach 
can enhance the efficacy of post-TQD treatment, as discussed below, but it has not been 
extensively studied to date.   
 
Varenicline and bupropion preloading demonstrated encouraging short-term effects in three 
small trials (6–8), while the results of NRT preloading have been more mixed (9,10). This 
could be in part due to some studies combining preloading with smoking reduction (11,12), a 
combination that may undermine the effect of preloading by reducing the opportunities for 
extinction learning (smoking with diminished rewards) and increasing the rewarding value of 
the remaining cigarettes. This is only a hypothesis though. Although e.g. the pioneering trial 
by Rose et al. found pre-loading with ad-lib smoking instructions effective (13) another trial 
5 
 
found no difference in outcomes in groups smoking their usual or reduced nicotine cigarettes 
for two weeks pre-quit (25); and a factorial experiment found a synergistic benefit of pre-quit 
patch use and pre-quit counselling that included a smoking reduction component, although 
there was no study arm with a counselling that omitted this or encouraged ad-lib smoking 
(14,15).  
 
We recently completed a large randomised trial of 4-weeks preloading with nicotine patches 
where participants were encouraged to smoke ad-lib during the preloading period; preloading 
facilitated quitting (16). 
 
The trial provides an opportunity to examine the putative ‘active ingredients’ of the 
preloading intervention. Preloading could in theory facilitate quitting in several distinct ways. 
Smokers may experience fewer urges to smoke (because e.g. the relevant receptors are 
stimulated by nicotine from NRT or occupied by varenicline) and this reduction of learned 
association between smoking behaviour and withdrawal relief (extinction of negative 
reinforcement) may facilitate quitting later. A reduced drive to smoke may also mean that a 
person will not smoke when s/he normally would, and in response to the usual smoking cues, 
which may weaken the power of the cues and situations to elicit a smoking response later. 
Preloading may also facilitate reduction of the enjoyment of smoking, i.e. positive 
reinforcement from smoking. Quitting a behaviour which by now provides limited 
satisfaction could be significantly easier than if smokers were quitting without preloading. 
The mechanisms described above could all reduce frequency and/or intensity of smoking, 
with such an extinction possibly occurring without much subjective experience of positive or 
negative effects. One consequence of all the above could be reduced cigarette dependence. 
Aside from these addiction-based mechanisms, three additional hypotheses can be 
formulated. Preloading may increase self-efficacy by generating a reduction in smoking with 
little effort. It may also assist with getting used to and in the habit of using the medication, 
and this could improve medication adherence after TQD. Finally, in a recent trial (17) we 
noticed that a proportion of participants who pre-loaded with patches reported developing an 
aversion to cigarettes. This was presumably because smoking increased systemic nicotine 
levels to the level that generates nausea and thus made smoking aversive. Aversion to 
cigarettes could thus be another mediator of the effects of preloading as aversive smoking is 
an effective cessation technique (24). Understanding the mechanism of action has important 
theoretical implications, but may also lead to a more effective use of this novel treatment. If 
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preloading is only effective in people who show early changes in relevant mediators, it could 
be stopped if the strategy is not achieving its intermediate effects. This would save resources 
and allow early implementation of alternative treatments. An insight into the mechanism of 
action can also lead to improvements in effectiveness. If for instance pre-loading works by 
making smoking aversive, increasing the medication dose could improve efficacy, while if 
extinction is the main mechanism, extending the pre-loading period could be helpful, etc.   
 
In this report, we use the data from the Preloading Trial to examine a range of possible 
effects of preloading on: 1) Positive reward from smoking, 2) Negative reward (alleviating 
boredom, calming effects etc), 3) The intensity of urges to smoke, 4) Smoking sterotypy, 5) 
Cigarette consumption and smoke intake, 6) Self-efficacy, 7) Nausea and aversion to 
smoking, 7) Post-TQD urges to smoke and cigarette withdrawal symptoms, 8) post-TQD 
medication use. We conducted mediation analysis using the causal inference approach to 
investigate the assumed causal pathways underlying the intervention. 
 
Methods 
Design:  In the main trial, participants were randomised to either standard smoking cessation 
medications accompanied by behavioural support or the same treatment supplemented by 
nicotine ‘preloading’, i.e. four weeks of 21mg nicotine patch use prior to quitting. Potential 
mediators were assessed at baseline and one week into the pre-loading (three weeks prior to 
quitting) and urges to smoke were also assessed in abstainers one week after the target quit 
date. We examined the effect of potential mediators on abstinence at four weeks and 6 
months post-TQD using path analysis (18). 
 
Main trial and its results: For trial details, see (19)(16). In brief, this was an open label trial 
with 1,792 smokers randomised 1:1 to non-use (N=893) or use (N=899) of a nicotine patch 
for four weeks prior to quit day. It was a multi-centre trial with study sites at Nottingham, 
Birmingham, Bristol and London.  Participants used standard pharmacotherapy of their 
choice, including NRT products, varenicline or bupropion, with NRT starting on TQD while 
the other medications starting 1-2 weeks earlier, as per usual practice.  They also received the 
standard behavioural support as provided by SSS, that typically comprises weekly support 
sessions over at least four weeks (20).  The primary outcome was prolonged biochemically 
validated abstinence at six months. Participants lost to follow-up or not providing 
biochemical validation were included as non-abstainers. In this open label trial with no 
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placebo control, participants assigned to patch preloading were less likely to use varenicline 
than the control group.  As in other trials (e.g. (21,22), varenicline use was associated with 
significantly higher quit rates than NRT use. When controlling for this imbalance, as pre-
specified in the trial protocol, the intervention showed a significant effect on smoking 
cessation at 1, 6 and 12 months with odds ratios of 1.32 (95% confidence interval [95% CI] 
1.08-1.62), 1.34 (95% CI: 1.03-1.73), and 1.36 (95% CI: 1.02-1.80), respectively. The 
preloading intervention comprising a provision of patches for four weeks prior to TQD 
appeared to be safe and well tolerated. 
 
Study arms: In the intervention arm, participants were asked to wear a 21mg 24-hour 
nicotine patch daily for four weeks prior to quit day. They were asked to smoke as normal 
and received a booklet outlining the rationale for the intervention and adherence support.  
 
We initially planned to use placebo patches in the control arm, but the funders did not allow 
this. To provide a plausible alternative, we asked participants to monitor their smoking 
pattern over the same time period, noticing the triggers for particular cigarettes, and to plan 
ways to avoid these cues after quit day.  The control arm received a booklet outlining this 
process, which was similar in length and appearance to the booklet given to the intervention 
group.   
 
Both study arms were referred to the local Stop Smoking Service (SSS) where a target quit 
date [TQD] was set between three and five weeks after enrolment. The Service provides 
‘withdrawal-oriented treatment’ (23) that comprises licensed medications (NRT – usually in 
combinations of patches and short-acting NRT forms, varenicline or bupropion – with these 
two medications normally not combined with NRT) together with weekly behavioural 
support starting 1-2 weeks prior to quit day and continuing until at least four weeks after quit 
day.  The medications were provided for up to three months. The study protocol allowed use 
of all stop-smoking medication regardless of preloading, necessitating a period of 
concomitant use  of varenicline and bupropion together with patches for one to two weeks 
pre-TQD.    
 
Timing of assessments: Participants were seen by researchers at baseline to collect data on 
mediators and to instigate interventions.  We reassessed participants one week later and again 
one week after their TQD, five weeks after commencing preloading.  The prime aim of these 
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assessments was to assess mediators, described below, and monitor adverse effects. Data on 
abstinence were collected at four weeks, six, and 12 months post-TQD.  Four-week outcome 
data were provided by the SSS, who validate abstinence by exhaled air carbon monoxide 
(CO) concentration. At six and 12 months after the TQD, we telephoned participants and 
invited those who claimed to be abstinent for at least a week to provide an exhaled CO 
reading.  Participants were compensated £15 for their time for attending this meeting.  
 
Measures:  
We report both 4-weeks and 6-months outcomes, but, given the former follow-up point is 
more proximate to the mediator variables we were studying, the primary focus is on 4-week 
smoking status. Abstinence was defined as no smoking at all for the previous two weeks 
validated by CO reading of <10ppm.   
 
Potential mediator variables were first measured one week after the start of preloading. Some 
measures related to responses to smoking were not included after quit day. The measures 
were:   
Positive reinforcement: Modified Cigarette Evaluation Questionnaire (mCEQ) Satisfaction 
Subscale (24). This comprises four items concerning satisfaction and enjoyment of smoking 
with scores ranging from 1=not at all to 7=extremely. Participants also rated whether their 
cigarettes were more or less enjoyable than previously. 
Negative reinforcement: mCEQ Reward Subscale. This comprises five items on whether 
smoking reduces irritability, provides a calming effect etc. with scores ranging from 1=not at 
all to 7=extremely. 
Drive to smoke: Ratings of strength and frequency of urges to smoke in the Mood and 
Physical Symptoms Scale Craving subscale (MPSS-C) (25) with scores ranging from 1=not 
at all to 6=extremely/all the time   and a question from a previous trial that asked participants 
to rate their urge to smoke compared with usual (6) with scores ranging from 1=much weaker 
to 5=much stronger.  We also analysed the mCEQ craving question (‘Did smoking it 
immediately relieve your craving for a cigarette?’, scored as other mCEO items).  We also 
included Fagerstrom Test of Nicotine Dependence (FTND) with the question about cigarette 
consumption removed as this was assessed directly as smoking behaviour. As withdrawal 
scores from people who continue to smoke are difficult to interpret (25), we analysed these 
after quit day only in participants who had remained abstinent or were continuing to try to be 
abstinent. 
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Smoking stereotypy: This comprised two items from Nicotine Dependence Syndrome Scale 
(NDSS), (26) , ‘I feel a sense of control over my smoking. I can ‘take it or leave it’ at any 
time’ and ’My smoking is not much affected by other things. I smoke about the same amount 
whether I’m relaxing or working, happy or sad, alone or with others, etc.’ with scores ranging 
from 1=not at all true to 5=extremely true.  (The other NDSS items relate to the amount 
smoke, that we measured directly).   
Changes in smoking behaviour: Reduction in cigarettes per day and in CO reading. 
Post-TQD medication adherence: Days of use of post-quit day medication measured at one-
week post-TQD. 
Self-efficacy: ‘How high would you rate your chances of giving up smoking for good at this 
attempt?’ with scores ranging from 1=not at all  to 5=extremely.    
Nausea and aversion during preloading: ‘Over the past week how nauseous have you felt 
when you have seen cigarettes or lighters’ and ‘Over the past week how nauseous have you 
felt when you have smelt cigarette smoke?’ with scores ranging from 1=not at all to 
5=extremely.   
Aversion was measured using the aversion subscale of the mCEQ that comprises two items 
asking whether smoking caused dizziness and nausea, scored as other mCEQ items above.  
 
Statistical analysis 
Mediation analysis was performed using the methods described by Valeri and Vanderweele 
(2013), to investigate the direct and indirect effects of preloading treatment on cessation at 4 
weeks and 6 months (ref as above). Initially, baseline characteristics were compared 
descriptively, and smoking outcomes at 1 week, 4 weeks and 6 months were compared 
descriptively, and using logistic regression to adjust for differences in varenicline use (pre-
specified in the trial protocol). We then tested the direct effect of treatment on each potential 
mediator (path a), using linear regression (analysis of covariance) to adjust for the baseline 
value of the mediator where appropriate. Since a variable can only be a mediator of treatment 
if there is a significant effect (p < 0.05) of treatment on the mediator (path a), subsequent 
mediation models were only fitted to variables that were significantly associated with 
preloading treatment.  To test the indirect (mediating) effect (ab path), we used the –
paramed- command in Stata to fit a logistic regression model to the cessation outcomes, with 
treatment and the relevant mediator included as covariates, and a linear regression model to 
the mediator including treatment as a covariate. In these models the mediators were fitted as 
the change from baseline (in accordance with our hypothesis that it is the change from 
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baseline which may mediate the observed treatment effect). The direct and indirect effects are 
then calculated from the coefficients of these models. The direct effect is interpreted as the 
influence of the intervention on the outcome that is not mediated by other variables in the 
model. More importantly, the indirect (mediated) effect expresses the portion of the treatment 
effect that is mediated through the specific mediator. This is estimated by how much the 
outcome would change if everyone in the study had the intervention and the mediator 
changed from its natural level had each individuals been assigned to the control, to its natural 
level had each individual been assigned to treatment (27). We also looked at the effect of 
adjusting for varenicline use measured at 1 week post quit date as a binary indicator, since 
this was a potential confounder which differed between treatment groups.  
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Results 
Table 1 shows sample characteristics including the baseline values of mediators. 
Table 1: Baseline characteristics, 4 week and 6 month outcomes by treatment group 
  
 Control 
N=893 
Mean (SD) 
Intervention 
N=899 
Mean (SD) 
Baseline   
Male (%) 469 (52.6) 473 (52.6) 
Age 48.8 (13.4) 49.1 (13.3) 
Smoking rate   
  Cigarettes per day 18.7 (9.0) 19.1 (9.6) 
  Exhaled CO 23.8 (12.8) 23.5 (12.3) 
FTND 4.1  (1.8) 4.1 (1.8) 
Positive reinforcement   
  mCEQ Satisfaction Subscale 4.4 (1.4) 4.4 (1.4) 
Negative reinforcement   
  mCEQ Reward Subscale 3.3 (1.5) 3.3 (1.5) 
Drive to smoke   
  MPSS-C 2.9 (1.0) 2.9 (0.9) 
  MPSS-M  2.0 (0.7) 2.0 (0.8) 
  Smoking stereotypy 2.1 (0.8) 2.1 (0.8) 
Confidence in quitting   
  How do you rate your 
chances? 
3.7 (0.8) 3.7 (0.8) 
Aversion   
Nausea 1.3 (0.6) 1.3 (0.6) 
mCEQ Aversion Subscale 1.4 (0.8) 1.5 (0.9) 
   
Abstinence at + 1 week* (%) 322 (36.1) 352 (39.1) 
   
Abstinence at 4 weeks* (%) 288 (32.2) 319 (35.5) 
   
Abstinence at 6 months* (%) 157 (17.5) 129 (14.4) 
   
Data represent the mean across items taken for all scales  
* Raw results, not adjusted for varenicline use. Non-responders included as non-abstainers. 
 
Effects of preloading intervention on potential mediators 
One week after the start of preloading: The effects of preloading on potential mediators are 
shown in the first part of Table 2. Preloading reduced both positive and negative reward from 
smoking. It also reduced three of the four measures of drive to smoke (there was no effect on 
MPSS mood symptoms). There was a modest but significant reduction in self-reported 
cigarette consumption (by 3 cigarettes/day, from a baseline mean of 19) and reduction in 
exhaled CO of 3ppm (from a baseline mean of 24 ppm).  The FTND score excluding 
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cigarette consumption also decreased. Both markers of aversion to smoking increased due to 
preloading. There was no evidence that confidence in quitting improved due to preloading.  
 
One week after TQD: Preloading was associated with a significant reduction in urges to 
smoke. There was no effect on withdrawal mood symptoms or on participants’ confidence in 
their ability to quit smoking.  Unlike in the pre-quit period, there was no evidence of a 
difference in nausea on seeing cigarettes after the quit day. There was also no evidence that 
preloading improved adherence to post-cessation medication. See Table 2.  
 
Table 2: Effect of the intervention on potential mediators  
 Control 
N=807-836* 
Mean (SD) 
Intervention 
N=844-863* 
Mean (SD) 
Difference between 
intervention and 
control** 
P 
value 
At week -3     
Positive reinforcement     
  mCEQ Satisfaction Subscale  4.1 (1.4) 3.6 (1.4) -.5 (-.7,-4) <0.001 
  Enjoyment more or less than   
usual 
2.7 (.7) 2.1 (.7) -.5 (-.6, -.5) <0.001 
Negative reinforcement     
  mCEQ Reward Subscale 2.9 (1.5) 2.6 (1.3) -.4 (-.5,-.2) <0.001 
Drive to smoke     
  MPSS-C 2.6 (0.9) 2.1 (.8) -.5 (-.6,-.4) <0.001 
  MPSS-M  1.9 (.7) 1.9 (.7) .04 (-.04, .06) 0.7 
  Smoking stereotypy 2.2  (.8) 2.3 (.8) .1 (.03, .2) 0.003 
  Urges stronger or weaker than 
usual 
2.9  (.7) 2.2 (.7) -0.82 (-.8, -.7) <0.001 
Smoking rate     
  Cigarettes per day 15.7 (8.7) 13.4 (8.3) -2.6 (-3.2,-2.1) <0.001 
  Exhaled CO 23.6 (12.8) 20.4 (11.7) -3.2 (-4.0,-2.3) <0.001 
FTND 3.9   (1.8) 3.6   (1.8) -.3 (-.4,-.2) <0.001 
Confidence in quitting     
  How do you rate your 
chances? 
3.8 (.8) 3.9 (.8) .03 (-.04, .09) 0.4 
Aversion     
  Nausea 1.3 (.6) 1.5 (.7) .2 (.1, .2) <0.001 
  mCEQ Aversion Subscale 1.3 (.7) 1.6 (1.0) .2 (.2, .3) <0.001 
     
At week +1 *** N=579-590* N=576-584*   
Drive to smoke     
  MPSS-C  1.5 (1.1) 1.3 (1.1) -.2 (-.3, -.1) 0.001 
  MPSS-M  1.8 (.7) 1.8 (.7) -.01 (-.1, .1) 0.8  
    
  Days used medication in last 
week  
0 
1-6 
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82 (14.2%) 
78 (13.5%) 
419 (72.4%) 
 
 
68 (11.7%) 
72 (12.3%) 
443 (76.0%) 
  
 
0.3 
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Data represent the mean across items taken for all scales  
* N varies due to missing data 
**Adjusted for baseline (where appropriate) to provide an estimate of the difference in change from 
baseline between groups 
***At week +1 (one week after quit day), the sample comprises only those who were abstinent or still 
trying to quit  
 
Association between mediators and smoking abstinence 
Table 3. shows the results of path analysis regarding abstinence at four weeks and Table 4. 
shows the effects at six months. 
Regarding objective effects, the reduction in exhaled CO was a significant mediator of the 
effect of pre-loading on abstinence at 4 weeks but narrowly missed significance at 6 months. 
The indirect effect suggests that smoking cessation would be increased by 4% if each 
participants reduced their CO reading by an average of 3.2 (as given in table 2).  
Among subjective ratings, rating urges to smoke as weaker than usual at -3 weeks was a 
significant mediator of the effect of pre-loading on abstinence at both 4 weeks and 6 months 
after adjustment for varenicline use. The indirect effect suggests that smoking cessation 
would be increased by 12% at 4 weeks and 16% at 6 months if each participant’s urges were 
reduced by an average of -0.8 on a 5 point scale (as seen in table 2).   
The reduction in urges to smoke assessed by MPSS at +1 week was also a significant 
mediator of the effect at both 4 weeks and 6 months. The indirect effect suggests that 
smoking cessation would be increased by 5% if urges to smoke were reduced by 0.2 points at 
one week post-TQD (as in table 2).  
  
Cigarette consumption, enjoyment, reward, craving, satisfaction, smoking stereotypy and 
aversion had no significant mediating effects at 4 weeks or 6 months. 
 
Table 3. Indirect, direct and total effects of the mediation models on abstinence at 4 
weeks  
 Natural Indirect 
(mediating) effect 
Controlled direct 
effect of treatment on 
outcome 
Total effect 
Change from baseline at -3 
weeks (unless otherwise 
indicated) 
   
Positive reinforcement    
  mCEQ satisfaction 
Unadjusted 
Adjusted for varenicline 
 
1.01 (0.96,1.05) 
1.01 (0.97,1.06) 
 
1.16 (0.94,1.42) 
1.24 (1.01,1.53) 
 
1.17 (0.96,1.42) 
1.26 (1.03, 1.55) 
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  Enjoyment more or less than 
usual  (at – 3weeks) 
Unadjusted 
Adjusted for varenicline 
 
 
0.99 (0.92,1.07) 
1.00 (0.92,1.08) 
 
 
1.19 (0.96,1.47) 
1.28 (1.02,1.59) 
 
 
1.17 (0.96,1.43) 
1.27 (1.04,1.56) 
Negative reinforcement    
  mCEQ reward  
Unadjusted 
Adjusted for varenicline 
 
1.00 (0.97,1.03) 
1.00 (0.98,1.03) 
 
1.18 (0.97,1.45) 
1.27 (1.03,1.57) 
 
1.18 (0.97,1.45) 
1.28 (1.04,1.57) 
Drive to smoke    
  MPSS-C 
Unadjusted 
Adjusted for varenicline  
 
1.01 (0.96,1.07) 
1.02 (0.97,1.08) 
 
1.16 (0.95,1.43) 
1.24 (1.01,1.54) 
 
1.17 (0.96,1.43) 
1.27 (1.04,1.56) 
  Smoking stereotypy 
Unadjusted 
Adjusted for varenicline 
 
1.00 (0.99,1.01) 
1.00 (0.99,1.01) 
 
1.18 (0.96,1.44) 
1.28 (1.04,1.58) 
 
1.18 (0.97,1.45) 
1.28 (1.04,1.58) 
  Urges stronger or weaker 
than usual 
Unadjusted 
Adjusted for varenicline 
 
 
1.10 (0.99,1.23) 
1.12 (1.00,1.25) 
 
 
1.06 (0.85,1.33) 
1.13 (0.90,1.43) 
 
 
1.17 (0.96,1.42) 
1.26 (1.03,1.55) 
Cigarette consumption 
Unadjusted 
Adjusted for varenicline 
 
0.97 (0.93,1.01) 
0.97 (0.93,1.01) 
 
1.20 (0.98,1.47) 
1.30 (1.06,1.61) 
 
1.17 (0.96,1.42) 
1.26 (1.03,1.55) 
  CO 
 Unadjusted 
Adjusted for varenicline 
 
1.04 (1.01,1.08) 
1.04 (1.01,1.08) 
 
1.10 (0.89,1.35) 
1.19 (0.96,1.46) 
 
1.14 (0.93,1.40) 
1.24 (1.01,1.53) 
FTND 
Unadjusted 
Adjusted for varenicline 
 
1.00 (0.97,1.02) 
1.00 (0.97,1.03) 
 
1.17 (0.95,1.43) 
1.27 (1.03,1.56) 
 
1.17 (0.95,1.42) 
1.27 (1.02,1.56) 
Aversion    
  Nausea 
Unadjusted 
Adjusted for varenicline 
 
0.98  (0.95,1.00) 
0.97 (0.95,1.00) 
 
1.20 (0.99,1.48) 
1.31 (1.06,1.60) 
 
1.18 (0.96,1.44) 
1.27 (1.04,1.56) 
  mCEQ aversion 
Unadjusted 
Adjusted for varenicline 
 
1.00 (0.97,1.02) 
1.00 (0.97,1.02) 
 
1.18 (0.96,1.44) 
1.27 (1.03,1.57) 
 
1.18 (0.96,1.44) 
1.27 (1.03,1.56) 
Change from baseline at +1 
week 
   
MPSS-C 
Unadjusted 
Adjusted for varenicline 
 
1.05 (1.01,1.09) 
1.05 (1.01,1.09) 
 
1.17 (0.93,1.48) 
1.23 (0.97,1.56) 
 
1.24 (0.98,1.56) 
1.30 (1.02,1.64) 
 
The controlled direct effect (CDE) expresses how much the outcome would change on average if the 
mediator were controlled at level m uniformly in the population, but the treatment were changed from control to treatment.  
The natural indirect effect (NIE) expresses how much the outcome would change on average if everyone received treatment 
but the mediator were changed from the level it would take on control to the level it would take on treatment.  
The total effect (TE) is defined as how much the outcome would change overall for a change in the exposure from control to 
treatment.  
 
Table 4. Indirect, direct and total effects of the mediation models on abstinence at 6 
months  
 Natural indirect 
(mediating) effect 
Controlled direct 
effect of treatment on 
outcome 
Total effect 
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Change from baseline at -3 
weeks (unless otherwise 
indicated) 
   
Positive reinforcement    
  mCEQ satisfaction  
Unadjusted 
Adjusted for varenicline 
 
1.04 (0.98,1.10) 
1.05 (0.99,1.11) 
 
1.17 (0.90,1.53) 
1.24 (0.95,1.61) 
 
1.22  (0.95,1.58) 
1.30 (1.00,1.68) 
  Enjoyment more or less than 
usual  (at –   3weeks) 
Unadjusted 
Adjusted for varenicline 
 
 
1.05 (0.96,1.16) 
1.06 (0.96,1.17) 
 
 
1.16 (0.88,1.52) 
1.22  (0.93,1.61) 
 
 
1.22 (0.94,1.57) 
1.29 (1.00,1.67) 
Negative reinforcement    
  mCEQ reward  
Unadjusted 
Adjusted for varenicline 
 
0.97 (0.93,1.01) 
0.98 (0.94,1.01) 
 
1.29 (0.99,1.68) 
1.35 (1.04,1.76) 
 
1.25 (0.97,1.62) 
1.32 (1.02,1.72) 
Drive to smoke    
  MPSS-C  
Unadjusted 
Adjusted for varenicline 
 
0.95 (0.89,1.03) 
0.96 (0.90,1.03) 
 
1.28 (0.98,1.67) 
1.35 (1.03,1.76) 
 
1.22 (0.95,1.58) 
1.30 (1.00,1.68) 
  Smoking stereotypy 
Unadjusted  
Adjusted for varenicline 
 
1.01 (0.99,1.02) 
1.01 (0.99,1.02) 
 
1.22 (0.94,1.58) 
1.29 (0.99,1.68) 
 
1.23 (0.95,1.59) 
1.30 (1.00,1.69) 
  Urges stronger or weaker 
than usual 
Unadjusted 
Adjusted for varenicline 
 
 
1.15 (1.00,1.32) 
1.16 (1.01,1.34) 
 
 
1.05 (0.79,1.41) 
1.10 (0.82,1.48) 
 
 
1.21 (0.94,1.57) 
1.28 (0.99,1.66) 
Cigarette consumption 
Unadjusted 
Adjusted for varenicline 
 
0.98 (0.93,1.04) 
0.98 (0.93,1.04) 
 
1.24 (0.95,1.61) 
1.31 (1.00,1.70) 
 
1.22 (0.94,1.57) 
1.29 (1.00,1.67) 
  CO  
Unadjusted 
Adjusted for varenicline 
 
1.04 (0.99,1.08) 
1.04 (0.99,1.08) 
 
1.15 (0.88,1.49) 
1.21 (0.93,1.58) 
 
1.19 (0.92,1.54) 
1.26 (0.97,1.63) 
FTND 
Unadjusted 
Adjusted for varenicline 
 
1.00 (0.96,1.03) 
1.00 (0.96,1.03) 
 
1.24 (0.96,1.61) 
1.32 (1.01,1.72) 
 
1.23 (0.95,1.60) 
1.31 (1.01,1.70) 
Aversion    
  Nausea 
Unadjusted 
Adjusted for varenicline 
 
1.01 (0.98,1.04) 
 
1.21 (0.93, 1.56) 
 
1.22 (0.94,1.57) 
  mCEQ aversion 
Unadjusted 
Adjusted for varenicline 
 
1.00 (0.97,1.03) 
1.00 (0.97,1.03) 
 
1.22 (0.94,1.58) 
1.29 (0.99,1.67) 
 
1.22 (0.94,1.57) 
1.29 (0.99,1.67) 
Change from baseline at +1 
week 
   
MPSS-C 
Unadjusted 
Adjusted for varenicline 
 
1.05 (1.01,1.09) 
1.05 (1.01,1.10) 
 
1.21 (0.92,1.60) 
1.24 (0.94,1.64) 
 
1.27 (0.97,1.60) 
1.31 (0.99,1.72) 
 
The controlled direct effect (CDE) expresses how much the outcome would change on average if the 
mediator were controlled at level m uniformly in the population, but the treatment were changed from control to treatment.  
The natural indirect effect (NIE) expresses how much the outcome would change on average if everyone received treatment 
but the mediator were changed from the level it would take on control to the level it would take on treatment.  
The total effect (TE) is defined as how much the outcome would change overall for a change in the exposure from control to 
treatment.  
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Discussion 
The preloading intervention affected a number of potential mediators, but there was evidence 
that only three of them mediated the effect of preloading on abstinence: The reduction in 
urges to smoke and reduction in smoke intake indexed by reduced CO readings one week 
after the start of preloading, and reduced urges to smoke post-quit.  
 
The study has several limitations. Key data on potential mediators were collected one week 
after commencing treatment. This was dictated by pragmatic considerations as the session 
was scheduled to allow early safety monitoring and dosing adjustment. However, logic and 
previous trials suggest that the effects of preloading on relevant variables increases with 
duration (6) and we may have seen stronger associations between preloading and change in 
mediators and between change in mediators and abstinence if this assessment had taken place 
later. Trial logistics however precluded more frequent contacts. Also, the timing of the 
assessments had the advantage of taking place at the stage when the largest number of 
participants might have been expected to adhere to preloading instructions and remain 
engaged in the trial.  Another limitation is that the open-label nature of the trial leaves open 
the possibility that some of the effects we detected were the result of participants’ 
expectations.  Participants in the intervention arm were told about the proposed mechanism 
of preloading to motivate them to adhere to the medication and this or other types of 
expectations may have influenced their questionnaire responses. We provided the control arm 
with a credible self-monitoring intervention to mitigate any expectation effects, but it is not 
clear if this did increase positive expectations and whether it could have affected some of the 
variables we examined. These issues however would be less likely to affect objective 
measures or measures collected post-quit. It is also reassuring that the two study arms did not 
differ in self-efficacy, which could be expected to be sensitive to expectation effects. We 
monitored a number of variables and although these were based on defined pathways, the 
results should be regarded as exploratory as we were testing several competing hypotheses.  
 
The finding related to reduced urges to smoke among those continuing their quit attempt at 
one week post-TQD needs to be interpreted with caution. Although those who had returned to 
smoking were excluded in both study arms which reduces the risk of bias, abstinence status 
was influenced by the intervention, and the finding therefore reflects the mediating effect in a 
subset of the original sample.  
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The study has several strengths.  We planned a comprehensive evaluation of the mechanism 
of action, assessing the full range of possible steps in the pathway, and we included analyses 
of competing hypotheses that have been advanced to explain the preloading effect. We also 
collected a comprehensive range of relevant variables. Finally, our trial included strict 
outcome measures and long-term follow-up, and it is by far the largest trial of preloading to 
date. 
 
Some of our findings tally with previous studies, but not all. Unlike some previous studies 
(28), we found that preloading reduced both positive and negative reward from smoking. Our 
trial is much larger than its predecessors and it is possible that previous trials may have 
missed the effect.  In a previous study of preloading with varenicline, there was a marked 
effect on enjoyment of smoking. This was considered to be one of the active ingredients of 
preloading treatments, though no mediator analysis was performed (6). Although in this 
study, preloading reduced smoking rewards as well, this did not mediate treatment effects. 
The main mediator was the reduction of urges to smoke. Varenicline preloading may have 
different effects than NRT preloading. Another possibility is that reduced enjoyment of 
smoking, while in this case not a significant mediator of abstinence on its own, could have 
still contributed indirectly, via urge reduction. Urge to smoke can be seen as consisting of a 
‘push’ driven by an internal need and a ‘pull’ via expected reward. In this hypothesis, 
blunting the reward could contribute to lowering the urge.  
 
In any case, the reduced drive to smoke appears to be the best candidate mechanism for the 
effect of preloading. The main objective mediator of treatment effects was reduced smoke 
intake. This can be interpreted as a consequences of reduced drive to smoke. This is an 
interpretation of the results that seems plausible to us, but other interpretations may be 
possible.   
 
The findings have implications for clinical practice and for future research.  If preloading 
were to be used routinely in smoking cessation treatments, therapists could monitor its early 
effect by asking users whether they have experienced reduced urge to smoke and by 
measuring CO levels, which is routine in most smoking cessation treatment centres. This 
would allow replacing preloading with other interventions if it appears to have no early 
effect. In terms of future work, if the main active ingredient is a reduction in the drive to 
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smoke, both increasing the nicotine dose and extending the pre-loading period could increase 
treatment effects and warrant further investigation.  
 
In summary, nicotine preloading appears to work because it reduces urges to smoke both 
prior to quitting, and after smoking cessation.  
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